Patient Home Monitoring (PHM) Appoints its Chairman Michael Dalsin as Chief Executive Officer

Patient Home Monitoring ("PHM") (TSX VENTURE:PHM), a profitable company focused
on rolling-up annuity-based healthcare service companies in the US and Canada,
today announced that it has appointed Chairman Michael Dalsin to the concurrent
position of Chief Executive Officer effective immediately. Mr. Andrew Folmer
will remain as President and CFO of PHM and continue to lead the company's
day-to-day operations. 


Mr. Dalsin is a merger and acquisition expert with a 15-year career as an
investment banker with international experience. He has a significant personal
shareholding in PHM and has co-led the acquisition strategy for PHM since June
2013. 


"I look forward to being more directly involved in PHM," said Michael Dalsin,
Chairman and CEO of PHM. "With our growing acquisition pipeline of over a dozen
potential target companies and the development of critical mass in revenue and
profit, the board believes I can serve more effectively as a leader in the
overall management of the business. While Andrew Folmer is doing a fantastic job
focusing on our profitability on a day-to-day basis, I believe we could increase
attention around capital markets and organic growth efforts. These will be my
two main areas of focus in addition to mergers and acquisitions." 


PHM also announced that all resolutions from its Annual General and Special
Meeting of Shareholders on April 11, 2014 were passed. 


About PHM 

PHM is currently a positive cash flow and profitable company that serves
patients with heart disease and other chronic health conditions, and will act as
a platform for acquisitions. PHM is focused on a highly fragmented and
developing market of small privately-held companies servicing chronically ill
patients with multiple disease states caused mainly by age and obesity. Because
of the new and highly fragmented nature of the market, PHM is actively working
to identify and evaluate profitable, annuity-based companies to acquire their
patient databases and technical expertise at favorable prices. PHM's post
acquisition organic growth strategy is to increase annual revenue per patient by
offering multiple services to the same patient, consolidating the patient's
services and making life easier for the patient. The expected result is growing
EPS with each acquisition and growing revenue and profits from the cross selling
efforts.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.  


This press release does not constitute and the subject matter hereof is not, an
offer for sale or a solicitation of an offer to buy, in the United States or to
any "U.S. Person" (as such term is defined in Regulation S under the U.S.
Securities Act of 1933, as amended (the "1933 Act")) of any equity or other
securities of PHM. The securities of PHM have not been registered under the 1933
Act and may not be offered or sold in the United States (or to a U.S. Person)
absent registration under the 1933 Act or an applicable exemption from the
registration requirements of the 1933 Act.


Forward-Looking Statements 

Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, dependence on few payors, possible new drug discoveries, a
novel business model, dependence on key suppliers, granting of permits and
licenses in a highly regulated business, competition, low profit market segments
as well as general economic, market and business conditions, and could differ
materially from what is currently expected.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Patient Home Monitoring Corp.
Michael Dalsin
Chairman
(323) 253-3055

Patient Home Monitoring Corp. (TSXV:PHM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024